Crealta Holdings to be purchased by Horizon Pharma | GlaxoSmithKline returns rights to 3 Amgen drugs | NephroGenex receives FDA OK for acute kidney injury treatment study
December 15, 2015
Bio SmartBrief

Today's Top Story
Crealta Holdings to be purchased by Horizon Pharma
Horizon Pharma has agreed to pay $510 million to buy Crealta Holdings. The transaction, which is expected to be completed in the first quarter of next year, will expand Horizon's orphan drug product pipeline to include Crealta's chronic refractory gout treatment, Krystexxa. Zacks (12/14)
Share: LinkedInTwitterFacebookGoogle+Email
Earn a free year of digital access to
The New York Times Crossword

Ready for a fun challenge? Ponder the daily puzzle, take a quick break with the mini, or explore the expansive archive to delight in the clever wordplay of the Crossword. Refer SmartBrief to 5 colleagues and enjoy a free year of unlimited access to The Crossword.
Your Referral Link:
Health Care & PolicySponsored By
GlaxoSmithKline returns rights to 3 Amgen drugs
Amgen has reacquired from GlaxoSmithKline the sales rights for three of its drugs in 48 countries. The drugs that will be returned are Amgen's osteoporosis drug Prolia; its advanced colorectal cancer treatment Vectibix; and XGeva, which is indicated for the prevention of bone fractures in cancer patients with bone metastases. GlaxoSmithKline will receive undisclosed upfront payments upon completion of the transaction. Reuters (12/14)
Share: LinkedInTwitterFacebookGoogle+Email
NephroGenex receives FDA OK for acute kidney injury treatment study
The FDA has cleared NephroGenex to initiate clinical trials for its intravenous acute kidney injury treatment, Pyridorin. The drug works by inhibiting the development of advanced glycation end-products, which is associated with diabetic kidney disease. (U.K.) (12/14)
Share: LinkedInTwitterFacebookGoogle+Email
Novartis' heart failure treatment gains NICE support
Draft guidelines have been released by the National Institute for Health and Care Excellence endorsing the use of Novartis' Entresto, a combination of sacubitril and valsartan, for the treatment of chronic heart failure. The recommendation is specifically for patients with reduced ejection fraction who are receiving a stable dose of ACE inhibitors and those with left ventricular ejection fraction of no more than 35%. The drug is already in the UK market through the Early Access to Medicines Scheme. PharmaTimes (U.K.) (12/14)
Share: LinkedInTwitterFacebookGoogle+Email
Myeloma drug from Takeda is launched in US
Takeda Pharmaceutical's oral proteasome inhibitor Ninlaro, or ixazomib, has been introduced in the US as a treatment for multiple myeloma. The drug is indicated for use in combination with lenalidomide and dexamethasone among previously treated patients. Chain Drug Review (12/11)
Share: LinkedInTwitterFacebookGoogle+Email
Saving Money, Saving Time in Pharma Operations
A holistic data infrastructure removes the barriers of finding, capturing, converting and organizing operational data, enabling operators and engineers to model enterprise-wide operational intelligence while reducing complexity and cost. Be on your way to better data, higher quality and more efficient operations.
Company & Financial News
Funding round brings in $30M for AltheaDx
A Series C funding round has brought in $30 million for AltheaDx. The firm intends to use the money for product improvement, growth opportunities and prospective studies for its IDgenetix assays, which use genetic markers to determine appropriate treatments for patients. GenomeWeb Daily News (free registration) (12/14)
Share: LinkedInTwitterFacebookGoogle+Email
The Latest From BIO ...
Are you looking for top biotech talent? Or looking for a biotech job?
Whether you are looking for a new job or a new addition to your team, Bio Jobs makes it easier than ever to find opportunities for talent in the biotech industry. Learn more at
Share: LinkedInTwitterFacebookGoogle+Email
Global Developments
Mitsubishi Tanabe acquires rights to Akebia's anemia drug
The rights to market Akebia Therapeutics' anemia drug vadadustat in Asia have been obtained by Mitsubishi Tanabe Pharma. Akebia will receive an upfront payment of $40 million, $60 million in funding for late-stage studies plus sales royalties. American City Business Journals/Boston (12/14)
Share: LinkedInTwitterFacebookGoogle+Email
Food & Agriculture
Malnourishment problem can be solved with biotech crops, expert says
Richard John Roberts, a Nobel laureate and molecular biologist, said that in addition to being safe, biotech crops such as golden rice are essential for solving malnourishment issues in developing countries. Roberts said opposition to biotech crops, which has prevented the use of golden rice, does not make sense, and he urged critics to stop claiming that biotech products pose a threat. The Hindu (India) (12/15)
Share: LinkedInTwitterFacebookGoogle+Email
Industrial & Environmental
Senator: EPA could face legal action over RFS
Sen. Chuck Grassley, R-Iowa, believes congressional and legal action will be taken against the Environmental Protection Agency over its decision on the Renewable Fuel Standard. "I think, quite frankly, they're violating the law. ... Congress could change that law, so it would take away any doubt whether they would have discretion to lower the [blending volume]," Grassley said. KMA-AM/KMA-FM (Shenandoah, Iowa) (12/14)
Share: LinkedInTwitterFacebookGoogle+Email
News From BIO
Savings on environmental waste disposal services
BIO has partnered with Clean Harbors, one of the largest environmental services companies in North America. The new BIO-Clean Harbors program will offer members a full range of hazardous and non-hazardous material management and disposal services at special pricing and deep discounts including 35-40% off list on disposal, 15-20% off list on transportation and materials and 35% off list price on labor charges. In addition, the BIO-Clean Harbors program offers full online tracking, free site visits to assure compliance with state and federal laws, staff training support and much more. Available to BIO or participating state and regional association members at no additional charge.
Share: LinkedInTwitterFacebookGoogle+Email
The Talent Hub for Biotech
powered by
Manager, Communications and Programs
CBI - Dist. Columbia
Each of us must work for his own improvement, and at the same time share a general responsibility for all humanity."
-- Marie Curie,
physicist and chemist
Share: LinkedInTwitterFacebookGoogle+Email
Learn more about BIO ->Conferences | Join Bio | Media | Issues | Industry
The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
Advertising:  Meryl Harold
  P: 202.407.7828
Editor:  Tara Rosenzweig

Download the SmartBrief App  iTunes / Android
iTunes  Android
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2015 SmartBrief, Inc.®
Privacy policy |  Legal Information